debt_leverage_profile
0.44x Total Debt / Equity (Conservative)
High
SEC-XBRL
interest_rate_sensitivity
High sensitivity; ~$50M+ debt load at variable/high rates means 200bps rise adds ~$1M+ annual interest expense, worsening already negative EBITDA
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Active ingredient sourcing from India/China API manufacturers; single-source botanical crofelemer from South American Croton lechleri bark harvests
Inferred
Agent_Inference
international_expansion_readiness
Minimal international revenue currently; primary exposure is EU/Latin America; crofelemer LatAm partnerships carry BRL and COP devaluation risk
Inferred
Agent_Inference
geographic_footprint
Predominantly US-based revenue (~90%+); limited LatAm and EU exposure; BRL, COP, and EUR devaluation risk modest but growing with partnership deals
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Salix Pharmaceuticals/Bausch supply relationship and single-source Croton lechleri botanical supplier represent non-substitutable >30% input dependency
Inferred
Agent_Inference
business_model_type_primary
Pharmaceutical commercial-stage company; cloud disruption risk low; operations are sales-force and manufacturing dependent, not cloud-infrastructure dependent
Inferred
Agent_Inference
business_model_type_secondary
Royalty and licensing revenue secondary model; cloud termination would disrupt CRM and order management but not core drug delivery or IP value
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; standard pharma ERP/CRM stack (Salesforce, SAP); no proprietary API dependencies; switching cost moderate but not operationally critical
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; revenue model is FDA-regulated prescription drug sales; no token, profit-sharing, or investment-contract structure present
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate HIPAA exposure from patient support programs; limited GDPR scope given minimal EU operations; CCPA applicable to California patient/HCP data
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; Mytesi holds small niche market share in HIV-diarrhea; no dominant market position or exclusionary conduct evident
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Predominantly transactional prescription drug sales (~80%); some recurring royalty/milestone revenue (~20%); no subscription model
Inferred
Agent_Inference
monetization_vector
Prescription drug dispensing revenue plus licensing/royalty fees from partnerships; transactional pharmacy channel dominant monetization vector
Inferred
Agent_Inference
pricing_architecture
WAC-based pharmaceutical pricing subject to PBM/payer rebate pressure; Mytesi WAC ~$900-1,000/month but net realized price significantly lower after rebates
Inferred
Agent_Inference
pricing_power_rating
Low-to-moderate; faces generic substitution threat long-term and payer formulary exclusion risk; limited pricing power without broader label expansion
Inferred
Agent_Inference
target_gross_margin_bracket
Reported gross margins ~60-70% on product revenue but SG&A-heavy structure yields deeply negative operating margins; net margin deeply negative
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider problem; prescription drug model requires active physician prescribing and patient adherence; high patient discontinuation rate is primary churn risk
Inferred
Agent_Inference
headcount_cost_structure
Headcount-linear growth model; scaling requires expanded sales force and medical affairs teams; doubling revenue likely requires ~60-70% headcount increase
Inferred
Agent_Inference
marginal_cost_of_growth
High marginal cost of growth; pharma detailing model requires proportional sales rep addition; limited operating leverage until significant revenue scale achieved
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; no franchise network; company operates direct pharmaceutical commercial model with contract sales organizations
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, physician detailing cost-per-prescriber likely improves ~30-40% via rep productivity; but payer negotiation complexity increases nonlinearly
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; prescription drug adoption driven by clinical evidence and physician habit, not user-network growth dynamics
Inferred
Agent_Inference
asset_efficiency_ratio
-140.9% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate recession resistance; Mytesi treats HIV-associated diarrhea (chronic condition), providing some demand stability, but patient cost-sharing sensitivity is real
Inferred
Agent_Inference
customer_segment_primary
HIV-positive patients experiencing antiretroviral-associated diarrhea; concentrated in urban HIV treatment centers and infectious disease specialist practices
Inferred
Agent_Inference
customer_segment_secondary
Oncology supportive care patients (diarrhea from targeted therapies/irinotecan); early-stage market development with high concentration in academic cancer centers
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
0.1% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0001585608
High
SEC-EDGAR
ticker
JAGX
High
SEC-EDGAR